Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Aurinia Pharmaceuticals Inc
Pre-Tax Income
Aurinia Pharmaceuticals Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Pre-Tax Income
-$61.7m
|
CAGR 3-Years
21%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-19%
|
|
Zymeworks Inc
NYSE:ZYME
|
Pre-Tax Income
-$119.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
Theratechnologies Inc
TSX:TH
|
Pre-Tax Income
-$17.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-7%
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Pre-Tax Income
-$103.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Pre-Tax Income
-$94.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
Spectral Medical Inc
TSX:EDT
|
Pre-Tax Income
-CA$15.5m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-3%
|
See Also
What is Aurinia Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
-61.7m
USD
Based on the financial report for Mar 31, 2024, Aurinia Pharmaceuticals Inc's Pre-Tax Income amounts to -61.7m USD.
What is Aurinia Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-19%
Over the last year, the Pre-Tax Income growth was 35%. The average annual Pre-Tax Income growth rates for Aurinia Pharmaceuticals Inc have been 21% over the past three years , and -19% over the past ten years .